Novo Nordisk A/S (NVO) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Novo Nordisk A/S

NYSE | NVO

57.89

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$259.42B

Market Cap

14.63

P/E Ratio

3.89

EPS

$117.23

52 Week High

$44.54

52 Week Low

HEALTHCARE

Sector

NVO Chart

Recent Chart

Price Action

NVO Technicals

Tags:

NVO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (DKK)
Gross Profit	$246B
Total Revenue	$290B
Cost Of Revenue	$45B
Costof Goods And Services Sold	$45B
Operating Income	$128B
Selling General And Administrative	$5.3B
Research And Development	$48B
Operating Expenses	$118B
Investment Income Net	-
Net Interest Income	-$91M
Interest Income	$1.8B
Interest Expense	$1.6B
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$8.5B
Income Before Tax	$127B
Income Tax Expense	$26B
Interest And Debt Expense	-
Net Income From Continuing Operations	$101B
Comprehensive Income Net Of Tax	-
Ebit	$129B
Ebitda	$137B
Net Income	$101B

Revenue & Profitability

Earnings Performance

NVO Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (DKK)
Total Assets	$466B
Total Current Assets	$161B
Cash And Cash Equivalents At Carrying Value	$16B
Cash And Short Term Investments	$16B
Inventory	$41B
Current Net Receivables	$87B
Total Non Current Assets	$305B
Property Plant Equipment	$162B
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$91B
Intangible Assets Excluding Goodwill	$91B
Goodwill	$20B
Investments	-
Long Term Investments	$2.7B
Short Term Investments	$11B
Other Current Assets	$6.3B
Other Non Current Assets	-
Total Liabilities	$322B
Total Current Liabilities	$218B
Current Accounts Payable	$29B
Deferred Revenue	-
Current Debt	-
Short Term Debt	$13B
Total Non Current Liabilities	$105B
Capital Lease Obligations	$6.8B
Long Term Debt	$84B
Current Long Term Debt	$12B
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$103B
Other Current Liabilities	$166B
Other Non Current Liabilities	$23M
Total Shareholder Equity	$143B
Treasury Stock	-
Retained Earnings	$144B
Common Stock	$446M
Common Stock Shares Outstanding	$4.5B

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (DKK)
Operating Cashflow	$121B
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$8.5B
Capital Expenditures	$51B
Change In Receivables	-
Change In Inventory	-$9B
Profit Loss	-
Cashflow From Investment	-$129B
Cashflow From Financing	$8.7B
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	$44B
Dividend Payout Common Stock	$44B
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-$20B
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	$101B

yearly Income Statement (As of Dec 31, 2024)

Field	Value (DKK)
Gross Profit	$246B
Total Revenue	$290B
Cost Of Revenue	$45B
Costof Goods And Services Sold	$45B
Operating Income	$128B
Selling General And Administrative	$5.3B
Research And Development	$48B
Operating Expenses	$118B
Investment Income Net	-
Net Interest Income	-$91M
Interest Income	$1.8B
Interest Expense	$1.6B
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$8.5B
Income Before Tax	$127B
Income Tax Expense	$26B
Interest And Debt Expense	-
Net Income From Continuing Operations	$101B
Comprehensive Income Net Of Tax	-
Ebit	$129B
Ebitda	$137B
Net Income	$101B

Dividends

Field	Value
Ex Dividend Date	2025-08-18
Declaration Date	2025-08-06
Record Date	2025-08-18
Payment Date	2025-08-26
Amount	0.584816

NVO News

NVO Profile

Novo Nordisk A/S Profile

Sector: HEALTHCARE

Industry: DRUG MANUFACTURERS - GENERAL

Novo Nordisk A/S is a leading global healthcare company based in Bagsvaerd, Denmark, specializing in the development and manufacturing of pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapy. With a strong focus on innovation and sustainability, Novo Nordisk leverages advanced biotechnology and scientific research to deliver effective solutions for chronic diseases. As a key player in the biopharmaceutical industry, the company is committed to improving patient outcomes while maintaining responsible business practices.

Symbol	Price	Change %	Market Cap	Volume
VHAI	$0.00	-25.00%	$2.64M	500,101,768
STAI	$0.62	+39.44%	$29.16M	228,870,836
CGBS	$0.03	-39.47%	$18.16M	197,485,133
YYAI	$0.15	-16.00%	$3.04M	194,112,134
DNN	$2.88	+1.76%	$2.56B	133,598,716

Symbol	Price	Change %	Market Cap	Volume
PFE	$24.67	-0.40%	$143.50B	7,503,851
BMY	$43.61	-0.77%	$92.45B	2,828,256
KVUE	$16.55	-0.57%	$32.32B	5,062,952
DOW	$37.19	-1.10%	$27.86B	5,523,226
HIMS	$55.43	+2.75%	$13.17B	4,552,079

Symbol	Price	Change %	Market Cap	Volume
LGCL	$3.91	+4002.82%	$12.95M	18,338
LPSN	$5.89	+1347.65%	$65.31M	119,466
PSIG	$4.38	+856.33%	$11.43M	111,826
CDT	$3.57	+627.97%	$2.34M	72,394
ELBM	$4.92	+198.75%	$34.11M	102,334,712

Symbol	Price	Change %	Market Cap	Volume
XELA	$0.00	-99.13%	$7.38M	12,512
GOTU	$3.03	-87.07%	$781.87M	103,622
TVRD	$6.24	-84.98%	$242.26M	3,466,243
SHOT	$0.39	-74.37%	$67.15M	13,958,900
PKBO	$0.02	-67.85%	$531.87K	66,140

Quick Links

NVO $0.00 (+0.00% ) Quote details